Evidence map›Paper›PMID 30822368›Full record

ReviewThe British journal of dermatology2019

Different definitions of atopic dermatitis: impact on prevalence estimates and associated risk factors.

T Nakamura, S Haider, S Colicino, C S Murray, J Holloway, A Simpson, P Cullinan, A Custovic, STELAR investigators

Open access · hybridAbstract readReview
In one paragraph

Review in The British journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Reply to BeckAmerican journal of respiratory and critical care medicine · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Annoying Psoriasis and Atopic Dermatitis: A Narrative Review.International journal of molecular sciences · 2022
    Review
  10. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.International archives of allergy and immunology · 2022
    Review
  11. Genetics of Asthma and Allergic Diseases.Handbook of experimental pharmacology · 2022
    Article
  12. Article
  13. Nomenclature and clinical phenotypes of atopic dermatitis.Therapeutic advances in chronic disease · 2021
    Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

T NakamuraDepartment of Paediatrics, Imperial College London, London, U.K.ORCID 0000-0002-5176-8277
S HaiderDepartment of Paediatrics, Imperial College London, London, U.K.
S ColicinoNational Heart and Lung Institute, Imperial College London, London, U.K.
C S MurrayDivision of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, U.K.ORCID 0000-0002-8961-8055
J HollowayHuman Development and Health, Faculty of Medicine, University of Southampton, Southampton, U.K.ORCID 0000-0001-9998-0464
A SimpsonDivision of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, U.K.ORCID 0000-0003-2733-6666
P CullinanNational Heart and Lung Institute, Imperial College London, London, U.K.
A CustovicDepartment of Paediatrics, Imperial College London, London, U.K.ORCID 0000-0001-5218-7071
STELAR investigators
Imperial College London · GBLung Institute · USUniversity of Manchester · GBUniversity of Southampton · GB

Funding

Medical Research Council G0601361Medical Research Council MR/K002449/1Medical Research Council MR/K002449/2
6 · The paper itself

Abstract

backgroundThere is no objective test that can unequivocally confirm the diagnosis of atopic dermatitis (AD), and no uniform clinical definition.

objectivesTo investigate to what extent operational definitions of AD cause fluctuation in the prevalence estimates and the associated risk factors.

methodsWe first reviewed the operational definitions of AD used in the literature. We then tested the impact of the choice of the most common definitions of 'cases' and 'controls' on AD prevalence estimates and associated risk factors (including filaggrin mutations) among children aged 5 years in two population-based birth cohorts: the Manchester Asthma and Allergy Study (MAAS) and Asthma in Ashford. Model performance was measured by the percentage of children within an area of clinical indecision (defined as having a posterior probability of AD between 25% and 60%).

resultsWe identified 59 different definitions of AD across 45 reviewed studies. Of those, we chose four common 'case' definitions and two definitions of 'controls'. The prevalence estimates using different case definitions ranged between 22% and 33% in MAAS, and between 12% and 22% in Ashford. The area of clinical indecision ranged from 32% to 44% in MAAS and from 9% to 29% in Ashford. Depending on the case definition used, the associations with filaggrin mutations varied, with odds ratios (95% confidence intervals) ranging from 1·8 (1·1-2·9) to 2·2 (1·3-3·7) in MAAS and 1·7 (0·8-3·7) to 2·3 (1·2-4·5) in Ashford. Associations with filaggrin mutations also differed when using the same 'case' definition but different definitions of 'controls'.

conclusionsUse of different definitions of AD results in substantial differences in prevalence estimates, the performance of prediction models and association with risk factors. What's already known about this topic? There is no objective test that can unequivocally confirm the diagnosis of atopic dermatitis (AD) and no uniform clinical definition. This results in different definitions utilized in AD studies, raising concerns on the generalizability of the results and comparability across different studies. What does this study add? This study has shown that different definitions of 'cases' and 'controls' have major impacts upon prevalence estimates and associations with risk factors, including genetics, in two population-based birth cohorts. These findings suggest the importance of developing a consensus on AD definitions of both 'controls' and 'cases' to minimize biases in studies.

Indexed as

Terminology as TopicCase-Control StudiesDermatitis, AtopicDermatologyFilaggrin ProteinsHumansLogistic ModelsPrevalenceResearch DesignRisk FactorsFilaggrin Proteins

Identifiers

PMID30822368
PMCPMC6916614
OpenAlexW2920674058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.